Predictive Oncology Inc.: insider trades · United States · SEC (Form 4)

About Predictive Oncology Inc.

Predictive Oncology Inc. was a U.S.-listed company on the Nasdaq Capital Market in the United States (United States). Historically, it positioned itself at the intersection of oncology, artificial intelligence, and translational research, with a mission centered on improving the discovery and development of cancer therapies. Its business model was built around proprietary AI and machine-learning platforms, a tumor-sample biorepository, and a CLIA laboratory intended to help identify drug-response patterns and support more informed therapy selection in oncology. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001446159/000117184325005375/poai20250630_10q.htm?utm_source=openai)) From a business-history perspective, the company developed a portfolio of science-driven assets focused on predicting tumor response and accelerating early drug discovery. A key platform was ChemoFx, a treatment-selection marker designed to quantify how a patient’s tumor responds in vitro to different chemotherapy agents. Management described it as initially focused on ovarian and other gynecological cancers, with a view toward broader application over time. The company also highlighted its proprietary bank of primary tumor samples as a strategic asset for model training, validation, and biomarker-driven research. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1446159/000117184325003205/exh_991.htm?utm_source=openai)) Operationally, Predictive Oncology previously combined oncology research, biomarker testing, and lab services with a medical-device business centered on STREAMWAY, a direct-to-drain medical fluid disposal system. A major recent development was the 2025 sale of the STREAMWAY-related assets, which the company reported as discontinued operations. That transaction materially narrowed the company’s operating footprint and shifted attention back toward its core oncology-related legacy business and its AI-enabled drug-discovery capabilities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001446159/000117184325004558/poai20250715_8k.htm?utm_source=openai)) In competitive terms, the company fit the profile of a small-cap specialty life-sciences player rather than a scaled commercial diagnostics platform. Its differentiation came from the combination of proprietary biological data, AI tooling, and a regulated laboratory environment. At the same time, the business remained exposed to typical development-stage risks: limited scale, dependence on external financing, and a continued lack of near-term profitability. The company itself stated that it was still seeking ways to improve cash flow from continuing operations and to strengthen revenue generation. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1446159/000117184325005375/poai20250630_10q.htm?utm_source=openai)) Geographically, the company was headquartered in Pittsburgh, Pennsylvania, United States, with operations historically tied to U.S.-based research and laboratory capabilities. Recent highlights included multiple 2025 updates on validation work for its AI platform, the divestiture of the STREAMWAY business, and a highly important strategic change in December 2025: Predictive Oncology changed its corporate name to Axe Compute Inc. and announced an expansion into high-performance enterprise AI infrastructure, while continuing to refer to its prior oncology operations as the legacy business. For investors, that means the equity story became a moving target: it is no longer just a pure oncology-technology narrative, but also a strategic transition story. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001446159/000117184325004558/poai20250715_8k.htm?utm_source=openai))